Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: beamtx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/28/2025 | $42.00 | Neutral → Buy | BofA Securities |
| 3/10/2025 | $40.00 | Sector Perform → Sector Outperform | Scotiabank |
| 1/29/2025 | Neutral → Overweight | Cantor Fitzgerald | |
| 11/6/2024 | $27.00 → $39.00 | Market Perform → Outperform | Leerink Partners |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 7/23/2024 | $80.00 | Buy | H.C. Wainwright |
| 1/29/2024 | $38.00 → $40.00 | Neutral → Overweight | JP Morgan |
| 12/15/2023 | $35.00 | Buy → Neutral | BofA Securities |
| 12/8/2023 | $75.00 → $30.00 | Buy → Hold | Jefferies |
| 10/20/2023 | Overweight → Neutral | Cantor Fitzgerald |